欧洲药品管理局关于特应性皮炎使用JAK抑制剂建议的详细解读
本文总结了欧洲药品管理局药物警戒风险评估委员会对口服JAK抑制剂获益-风险再评估后的建议,尤其关注特应性皮炎的应用背景;委员会建议≥65岁或有心血管疾病史、其他心血管危险因素或恶性肿瘤危险因素的患者,仅在无合适替代方案时使用口服JAK抑制剂,有肺栓塞或深静脉血栓风险者慎用;作者认为已获批用于特应性皮炎的JAK抑制剂获益-风险特征仍有利,包括对<65岁且无心血管或恶性肿瘤危险因素患者的系统性一线治疗。
要点
- PRAC建议≥65岁或有心血管疾病史、其他心血管危险因素或恶性肿瘤危险因素的患者,仅在无合适替代方案时使用口服JAK抑制剂。
- 有肺栓塞或深静脉血栓风险的患者应慎用口服JAK抑制剂。
- 已获批用于特应性皮炎的JAK抑制剂获益-风险特征仍有利,包括<65岁且无心血管或恶性肿瘤危险因素患者的一线系统性治疗。
核心结论
- 已获批用于特应性皮炎的JAK抑制剂获益-风险特征仍有利,包括作为<65岁且无心血管或恶性肿瘤危险因素患者的一线系统性治疗。
研究设计与样本
- 作者总结了PRAC对口服JAK抑制剂的建议、口服JAK抑制剂安全性的新临床证据以及类风湿关节炎与特应性皮炎患者的关键差异。
主要发现
- 类风湿关节炎患者发生特殊关注的不良事件(如心血管事件、恶性肿瘤)的风险高于特应性皮炎患者,因为其潜在危险因素的患病率更高。
关键数值与推荐
- PRAC建议口服JAK抑制剂仅用于≥65岁或无合适替代方案的患者,以及有动脉粥样硬化性心血管疾病史、其他心血管危险因素(如长期吸烟史)或恶性肿瘤危险因素的患者;有肺栓塞或深静脉血栓风险的患者慎用。
- 欧洲委员会的最终决定于2023年3月发布。
临床怎么用
- 在特应性皮炎患者中使用口服JAK抑制剂时,应评估年龄(≥65岁)、动脉粥样硬化性心血管疾病史、其他心血管危险因素(如长期吸烟史)、恶性肿瘤危险因素以及肺栓塞或深静脉血栓风险,并遵循PRAC建议:仅在无合适替代方案时用于≥65岁或有上述危险因素的患者,有血栓风险者慎用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral Janus kinase inhibitors (JAKi) have been approved for the treatment of several chronic inflammatory conditions, including rheumatoid arthritis (RA) and atopic dermatitis (AD). Prompted by new evidence, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recently reassessed the benefit-risk balance of oral JAKi. The PRAC recommended that oral JAKi should be used only if no suitable alternatives are available in patients ≥65 years of age, or who have a history of atherosclerotic cardiovascular (CV) disease, other CV risk factors (e.g. history of long-term smoking) or have malignancy risk factors, and used with caution in patients at risk of pulmonary embolism or deep vein thrombosis. The European Commission's final decision was issued in March 2023. OBJECTIVES: Our goal was to highlight the PRAC recommendations, especially in the context of oral JAKi use in AD. METHODS: Authors summarized the PRAC recommendations, the new clinical evidence on oral JAKi safety and key differences between patients with RA and AD. RESULTS: Risk of developing adverse events of special interest (e.g. cardiovascular events, malignancy) is higher in patients with RA than in patients with AD, because of the higher prevalence of the underlying risk factors. CONCLUSIONS: The benefit-risk profile of JAKi approved for AD remains favourable, including use as first-line systemic therapy for patients with AD <65 years of age and without CV or malignancy risk factors.
引用
- Wollenberg A, Thyssen JP, Bieber T, et al. A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2023. PMID: 37319107. doi:10.1111/jdv.19255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。